A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia.
Genetic contributions to the etiology of substance abuse and dependence are topics of major interest. Acute and chronic cannabis use can produce drug-induced psychosis resembling schizophrenia and worsen positive symptoms of schizophrenia. The endocannabinoid system is one of the most important neural signaling pathways implicated in substance abuse and dependence. The fatty acid amide hydrolase (FAAH) is a primary catabolic enzyme of endocannabinoids. To clarify a possible involvement of FAAH in the etiology of methamphetamine dependence/psychosis or schizophrenia, we examined the genetic association of a nonsynonymous polymorphism of the FAAH gene (Pro129Thr) by a case-control study. We found no significant association in allele and genotype frequencies of the polymorphism with either disorder. Because the Pro129Thr polymorphism reduces enzyme instability, it is unlikely that dysfunction of FAAH and enhanced endocannabinoid system induce susceptibility to either methamphetamine dependence/psychosis or schizophrenia.
Morita
Yukitaka
Y
Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Ujike
Hiroshi
H
Tanaka
Yuji
Y
Uchida
Naohiko
N
Nomura
Akira
A
Ohtani
Kyohei
K
Kishimoto
Makiko
M
Morio
Akiko
A
Imamura
Takaki
T
Sakai
Ayumu
A
Inada
Toshiya
T
Harano
Mutsuo
M
Komiyama
Tokutaro
T
Yamada
Mitsuhiko
M
Sekine
Yoshimoto
Y
Iwata
Nakao
N
Iyo
Masaomi
M
Sora
Ichiro
I
Ozaki
Norio
N
Kuroda
Shigetoshi
S
D000328:Adult; D017668:Age of Onset; D000581:Amidohydrolases / Q000235:genetics*; D000595:Amino Acid Sequence / Q000235:genetics; D019943:Amino Acid Substitution / Q000235:genetics; D019969:Amphetamine-Related Disorders / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D012559:Schizophrenia / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D063385:Cannabinoid Receptor Modulators; D008694:Methamphetamine; D000099252:Fatty Acid Amide Hydrolases